Nasus Pharma Ltd

NSRX NYSE SEC CIK 2029039
Follow Nasus Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$6M−$4M−$2M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$5.9M
FY24−$1.5M
FY23−$1.1M
FY22-